Viral Load (VL) | |||||
---|---|---|---|---|---|
Characteristics | Detectable n (%) | Undetectable n (%) | PR | PR 95% IC | P-value |
Age (years) | 0, 662a | ||||
18–30 | 6 (11, 5) | 13 (12, 2) | 0, 92 | 0, 45 – 1, 86 | |
31–50 | 40 (76, 9) | 76 (71, 0) | 1, 00 | – | |
> 50 | 6 (11, 5) | 18 (16, 8) | 0, 73 | 0, 35 – 1, 52 | |
Gender | 0, 385a | ||||
Male | 36 (69, 2) | 81 (75, 7) | 0, 81 | 0, 50 – 1, 29 | |
Female | 16 (30, 8) | 26 (24, 3) | 1, 00 | – | |
VL on genotypic result (copies/ml) | 0, 752a | ||||
≤ 10.000 | 18 (35, 3) | 36 (34, 3) | 1, 00 | – | |
> 10.000 a 100.000 | 20 (39, 2) | 47 (44, 7) | 0, 90 | 0, 53 – 1, 52 | |
> 100.000 | 13 (25, 5) | 22 (21, 0) | 1, 11 | 0, 63 – 1, 98 | |
CD4 on genotypic result (cells/mm3) | 0, 796a | ||||
< 200 | 20 (38, 5) | 45 (42, 9) | 0, 95 | 0, 54 – 1, 66 | |
200–350 | 18 (34, 6) | 31 (29, 5) | 1, 13 | 0, 64 – 1, 99 | |
> 350 | 14 (26, 9) | 29 (27, 6) | 1, 00 | – | |
Number of NRTI resistance mutations | 0, 179a | ||||
zero | 6 (11, 6) | 10 (9, 3) | 1, 00 | – | |
< 3 | 32 (61, 5) | 52 (48, 6) | 1, 02 | 0, 51 – 2, 02 | |
≥ 3 | 14 (26, 9) | 45 (42, 1) | 0, 63 | 0, 29 – 1, 38 | |
N° of thymidine analogue mutation | 0, 058a | ||||
zero | 35 (67, 3) | 54 (50, 4) | 1, 00 | – | |
< 3 | 14 (26, 9) | 34 (31, 8) | 0, 74 | 0, 45 – 1, 24 | |
≥ 3 | 3 (5, 8) | 19 (17, 8) | 0, 35 | 0, 12 – 1, 02 | |
Number of NNRTI resistance mutations | 0, 113a | ||||
≤ 2 | 32 (61, 5) | 79 (73, 8) | 1, 00 | – | |
> 2 | 20 (38, 5) | 28 (26, 2) | 1, 45 | 0,93 – 2,25 | |
Number of PI resistance mutations | 1, 000b | ||||
≤ 2 | 4 (80, 0) | 14 (77, 8) | 1, 00 | – | |
> 2 | 1 (20, 0) | 4 (22, 2) | 0, 90 | 0, 13 – 6, 35 | |
M184 V/I mutation | 0, 693a | ||||
Yes | 44 (84, 6) | 93 (86, 9) | 1, 00 | – | |
no | 8 (15, 4) | 14 (13, 1) | 1, 13 | 0, 62 – 2, 07 |